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Abstract
More than 90% of cancer mortalities are due to cancer that has metastasized. Therefore, it is crucial to intensify research on
metastasis formation and therapy. Here, we describe for the first time the metastasizing ability of the human cervical cancer
cell line C33A in athymic nude mice after subcutaneous implantation of tumor cells. In this model, we demonstrated a
steady progression of lumbar and renal lymph node metastases during tumor development. Besides predominantly
occurring lymphatic metastases, we visualized the formation of hematogenous metastases utilizing red fluorescent protein
(RFP) expressing C33A-RFP cells. RFP positive cancer cells were found migrating in blood vessels and forming
micrometastases in lungs of tumor-bearing mice. Next, we set out to analyze the influence of oncolytic virotherapy in the
C33A-RFP model and demonstrated an efficient virus-mediated reduction of tumor size and metastatic burden. These
results suggest the C33A-RFP cervical cancer model as a new platform to analyze cancer metastases as well as to test novel
treatment options to combat metastases.
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Introduction
Metastatic spread of tumors is a multistage process during which
malignant cells disseminate from the primary tumor to distant
organs [1]. Tumor cells migrate via two major routes: The
lymphatic system and the blood circulation. During lymphatic
metastasis, a common feature for most carcinomas, tumor cells
leave the original tumor site and migrate after settlement in
regional lymph nodes to distant ones [2]. Diagnosis of lymph node
metastases is of major importance. Even though, lymph node
metastases themselves are rarely life threatening they indicate the
state of tumor progression [3]. Most cancer deaths are due to
development of metastases. Therefore, a broader understanding of
the biology of metastases is necessary. Three major platforms are
currently used to develop in vivo metastasis models. These include
chemical induction, whereby carcinogens are administered to
induce tumorigenesis and metastasis, syngeneic and xenograft
transplant models that involve the transplantation of tumor cells/
tissue into murine hosts and genetically engineered mouse models
[4–5]. Here, we are working with a xenogeneic spontaneous
transplant model of metastasis. A number of xenogeneic metastasis
models have been generated during the last years, for example, for
prostate [6–8], colorectal [9–10], breast [11–12], gastric [13–14]
or renal cell [15] carcinomas. Additionally, there are also some
models of human papillomavirus (HPV) positive cervical cancer
described [16–18].
In the course of a cervical cancer screening study (HPV positive
and HPV negative cell lines) for oncolytic virotherapy the effects of
the oncolytic vaccinia virus GLV-1h68 on these cell lines was
analyzed. The results indicate that the presences and the copy
number of HPV DNA in cervical cancer cells did not have an
impact on the therapeutic efficacy of GLV-1h68 (Table S1).
Furthermore we discovered the formation of lymph node
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metastases after subcutaneous implantation of C33A HPV-
negative human cervical cancer cells in immunocompromised
mice. Therefore, in this study, we focused on the characterization
of the metastasizing ability of this cell line, which has not been
described in the literature so far. We analyzed the lymphatic and
the hematogenous spread of C33A-RFP cells in nude mice after
subcutaneous implantation of tumor cells, whereby lymphatic
circulation represented the main route of metastasizing tumor
cells. Moreover, a steady progression of lymph node metastases in
correlation with the tumor growth was demonstrated.
In addition, we analyzed oncolytic virotherapy of C33A tumors
and metastases as a novel treatment option. Oncolytic viruses are
able to selectively replicate in cancer cells, resulting in destruction
of tumor tissue, but leaving healthy tissues unharmed [19]. Here,
we focused on studying the effect of the previously described
attenuated, recombinant vaccinia virus GLV-1h68 [20–21]. The
therapeutic effect of this virus on primary tumors has been shown
for many carcinomas such as breast, pancreatic or prostate cancer
[21–23]. Furthermore, we recently showed a therapeutic potential
of GLV-1h68 in treating lymphatic and hematogenous metastases
originating from the human prostate carcinoma cell line PC-3
[22], indicating that GLV-1h68 might be able to eradicate
metastases in the C33A-model as well. Indeed, here we
demonstrated a drastic virus-mediated reduction of C33A-RFP
tumors and their metastatic burden.
Materials and Methods
Cell lines
The HPV-negative human cervical cancer cell line C33A was
cultured in DMEM High Glucose (PAA Laboratories, Co¨lbe,
Germany) supplemented with 10% FCS (PAA Laboratories,
Co¨lbe, Germany) and 1% gentamicin solution (PAA Laboratories,
Co¨lbe, Germany). The C33A cell line was kindly provided by
Frank Stubenrauch, PhD (UKT, University of Tu¨bingen; [24]).
Authenticity of C33A cells was verified by the DSMZ GmbH
(Leibniz Institute DSMZ-German Collection of Microorganisms
and Cell Cultures, Braunschweig, Germany). C33A-RFP cells
were cultured under same conditions except for adding 5 mg/mL
blasticidin. Human epithelial kidney cells (293FT) were obtained
from Invitrogen GmbH (Karlsruhe, Germany) and cultured in
RPMI 1640 supplemented with 10% FCS and 2 mM L-glutamine
(PAA Laboratories, Co¨lbe, Germany).
Generation of C33A-RFP cells
The cDNA sequence of the red fluorescent protein (mRFP1) was
inserted into the C33A cell genome using Vira Power Lentiviral
Expression System Kit (Invitrogen GmbH, Germany) in accor-
dance with the manufacturer’s instructions. The mRFP1-encoding
plasmid pCR-TK-SEL-mRFP was provided by Q. Zhang
(Genelux Corporation, San Diego) and used to generate the
mRFP1-containing lentiviral vectors as described previously [25].
Replication-incompetent mRFP1-encoding lentiviruses were pro-
duced in 293FT cells by co-transfection of the plasmids pLP1,
pLP2, pLP/VSVG that supply lentiviral structural and replication
proteins and the pLENTI6/V5-DEST-mRFP expression plasmid
using LipofectamineTM2000. After transduction of C33A cells with
mRFP-encoding lentiviruses and blasticidin (5 mg/mL) selection,
one stable RFP expressing C33A clone was selected.
Virus strain
The attenuated vaccinia virus strain GLV-1h68 was previously
described by Zhang et al. [21]. Three expression cassettes encoding
for Renilla luciferase-GFP fusion protein, b-galactosidase, or b-
glucuronidase were recombined into the F14.5L, J2R and A56R
loci, respectively, of the parental LIVP virus genome.
Ethics statement
All animals were cared for and handled in strict accordance
with good animal practices as defined by the national and local
animal welfare bodies (Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health and the
German Animal Welfare Act ‘‘TierSchG’’). Experimental proto-
cols were approved by the government of Unterfranken, Germany
(protocol numbers 55.2-2531.01-17/08 and 55.2-2531.01-25/12)
and/or the Institutional Animal Care and Use Committee
(IACUC) of Explora BioLabs, located in San Diego Science
Center (San Diego, USA) (protocol numbers: EB08-003; EB11-
025).
Tumor implantation and virus administration
Tumors were generated by implanting 56106 C33A-RFP cells
in 100 mL PBS subcutaneously into the right abdominal flank of 6-
8 weeks old female athymic nude Foxn1nu mice (Harlan
Winkelmann GmbH, Borchen, Germany). Tumor and lymph
node volume was monitored in two dimensions using a digital
caliper and calculated as [(length)6(width)260.52]. Tumor volume
was measured in living mice, whereas lymph node volume was
measured post mortem, after opening the abdomen. A lymph node
was defined to be enlarged when the maximal diameter exceeded
3 mm. For studying the effect of oncolytic virotherapy a single
dose of 56106 plaque forming units (pfu) of GLV-1h68 in 100 mL
PBS was injected intravenously (i.v.) into C33A-RFP tumor-
bearing mice, after the tumor volume reached 200–250 mm3.
Mice were sacrificed according to the Guidelines for Euthanasia of
Rodents using carbon dioxide.
Fluorescence imaging
Images of C33A-RFP tumor-bearing mice were taken with the
Maestro EX Imaging System (Caliper, Hopkinton, MA, USA).
Fluorescence imaging of tumors, kidneys, lungs and lymph nodes
of C33A-RFP tumor-bearing mice was performed with a MZ16
FA Stereo-Fluorescence Microscope (Leica, Wetzlar, Germany).
For imaging of mice with the Maestro EX Imaging System,
animals were anesthetized using 2-3% isoflurane. Digital images
were processed with Photoshop 7.0 (Adobe Systems, Mountain
View, USA).
Measurement of fluorescence intensity
Measurement of the fluorescence intensity of the RFP signal in
lymph nodes and kidneys of C33A-RFP tumor-bearing mice was
performed using ImageJ (http://rsbweb.nih.gov/ij). RGB-images
of the RFP signal of kidneys and lymph nodes were converted into
8-bit gray scale with an intensity range from 0–255. The
fluorescence intensity represents the average brightness of all
RFP related pixels.
Immunohistochemistry
For histology, tumors, lymph nodes and kidneys were excised
and fixed for 16 h in 4% paraformaldehyde/PBS, pH 7.4.
Preparation of 100 mm sections and labeling procedures were
performed as described previously [26] using the Leica VT1000
Vibratom (Leica, Heerbrugg, Switzerland). After labeling, tissue
sections were mounted in Mowiol 4–88 (Sigma-Aldrich, Tauf-
kirchen, Germany). For preparation of 10 mm sections tissue
samples were sectioned with the cryostat 2800 Frigocut (Leica,
Wetzlar, Germany). After dehydration in 10% and 30% sucrose
Metastasis and Virotherapy of a C33A Cancer Model
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e98533
(Carl Roth, Karlsruhe, Germany) specimens were embedded in
Tissue-Tek O.C.T. (Sakura Finetek Europe B.V., Alphen aan den
Rijn, Netherlands). Cryo-sections were stored at 280uC and
incubated with primary antibodies for 1 h. After washing with
PBS, sections were stained for 1 h with secondary antibodies and
finally mounted in Mowiol 4–88.
Antibodies and reagents
Endothelial blood vessels were stained with a hamster mono-
clonal anti-CD31 antibody (Chemicon International, Temecula,
USA; MAB1398Z) and endothelial lymph vessels with a rabbit
polyclonal anti-LYVE-1 antibody (Abcam, Cambridge, UK;
ab14917). Nuclei were Hoechst 33342-labeled (Sigma Aldrich,
Taufkirchen, Germany). DyLight488-conjugated secondary anti-
bodies (donkey) were obtained from Jackson ImmunoResearch
(Pennsylvania, USA). Primary and secondary antibodies were
diluted 1:100 in PBS/0.3% Triton-X-100.
Fluorescence microscopy
Images of tumor, lymph node and kidney sections were
captured with the following microscopes: A stereo-fluorescence
microscope MZ16 FA (Leica) equipped with a digital CCD
camera and the Leica IM1000 4.0 software (130061030 pixel
RGB-color images), a TCS SP2 AOBS confocal laser microscope
(Leica) equipped with the LCS 2.16 software (102461024 pixel
RGB-color images) and a Axiovert 200 M microscope (Zeiss) with
Axiovision 4.5 software (138861040 pixel gray scale images),
respectively. Digital images were processed with Photoshop 7.0
(Adobe Systems, USA) and merged to yield pseudo-colored
pictures. Images of cells seeded in 24 well plates were captured
either with the stereo-fluorescence microscope MZ16 FA (Leica)
or with the Axiovert 200 M microscope (Zeiss).
Preparation of single cell suspensions and FACS analysis
For preparing single cell suspensions of tumors, lumbar and
renal lymph nodes, lungs and kidneys of C33A-RFP tumor-
bearing mice tissues were weighed, minced and incubated
individually in DMEM High Glucose media supplemented with
2% FCS, 10.000 U/mL Collagenase I (Sigma, Steinheim,
Germany) and 5 MU/mL DNase I (Calbiochem, Darmstadt,
Germany) at 37uC. Tumor tissues were incubated for 35 min, LN
and RN tissues for 30 min, kidneys for 20 min and lungs for
15 min. Subsequently, tissues were passed through 70 mm nylon
mesh filters (BD Biosciences, Erembodegem, Belgium) and
transferred to DMEM High Glucose media supplemented with
2% FCS. After centrifugation (1000 g, 10 min) pellets were
resuspended in 2x volume of PBS/2% FCS, regarding to tissue
weight. Subsequent, 100 mL of the single cell suspensions were
analyzed using Accuri C6 Cytometer and FACS analysis software
CFlow Version 1.0.227.4 (Accuri Cytometers, Inc. Ann Arbor,
MI, USA). Cells were gated according to their size (FSC) and
granularity (SSC). Furthermore, 100 mL of the single cell
suspensions were seeded into 24 well plates in 161021 to
161024 dilutions. Dilutions were prepared in DMEM High
Glucose media supplemented with 10% FCS. Three days after cell
suspension seeding media was supplemented with 5 mg/mL
blasticidin, to select C33A-RFP cells. Cell washing and media
renewal were performed twice a week. After one week of
blasticidin selection C33A-RFP cells in the 24 well plates were
stained with crystal violet for 3 h, washed and dried. Afterwards,
cell colonies were counted.
Statistical analysis
A two-tailed Student’s t test was used for statistical analysis. P
values of #0.05 were considered statistically significant. Asterisks
indicate a significant difference between experimental groups (*
indicates p#0.05; ** indicates p#0.01; *** indicates p#0.001).
Results
Growth kinetics of subcutaneous C33A-RFP tumors and
lymph node metastases formation
An observed enlargement of lumbar and renal lymph nodes in
C33A tumor-bearing mice indicated the presence of metastasized
tumor cells. To enable visualization of metastatic C33A cell
spread, the cDNA sequence of the red fluorescent protein (mRFP1)
was inserted into the C33A cell genome. Expression of RFP in
C33A cells was confirmed by fluorescence microscopy (Fig. 1a).
Subsequently, 56106 C33A-RFP cells were subcutaneously (s.c.)
implanted into the right flank of nude mice. Every week up to 49
days post implantation six to seven C33A-RFP tumor-bearing
mice were examined. As a part of these analyses volumes of
tumors, lumbar (LN1, LN2) and renal (RN1, RN2) lymph nodes
were measured (Fig. 1b+c) and fluorescence imaging of tumors
and lymph node metastases was performed (Fig. 1d). We showed a
steady increase of the tumor volume from week to week after
implantation of C33A-RFP cells. At the same time, the volumes of
lumbar and renal lymph nodes were increasing as well, indicating
a possible tumor cell colonization process resulting in lymph node
volume expansion. Fluorescence imaging confirmed RFP signals
in the enlarged lymph nodes, demonstrating C33A-RFP metasta-
ses. Notably, the volume of LN1, the lumbar lymph node located
closest to the primary C33A-RFP tumor, was increasing first and
largest, as would be expected for regional lymph node metastases.
Moreover, fluorescence imaging during the time course of 49
days revealed a steady increase of the amount of lymph nodes
positive for RFP after tumor cell implantation, starting with 21%
RFP positive lymph nodes at day 7. The amount increased to 88%
lymph nodes positive for RFP expression at the end of the
experiment (Fig. 1e). Furthermore, the percentage of RFP positive
LN1, LN2, RN1 and RN2 was analyzed per time point. At day 7
post implantation 86% of all detected LN1s were positive for RFP,
whereas no RFP signal was detectable in LN2, RN1 or RN2
leading to the assumption that metastatic colonization with C33A-
RFP cells occurs first in the regional lymph node LN1. Fourteen
days post tumor cell implantation (dpti) all detected LN1s (100%)
and 50% of RN1s were positive for RFP, indicating that after
metastasizing to LN1 the C33A-RFP cells spread to the next local
lymph node (renal lymph node RN1). Metastasized C33A-RFP
cells in LN2 and RN2 were first detected at day 28 post
implantation (Fig. 1f). Taken together, we showed a continuous
progression of metastasis of lumbar and renal lymph nodes
coinciding with the C33A-RFP tumor growth from week to week
after s.c. tumor cell implantation.
C33A-RFP tumor cells metastasize via both the lymphatic
and the hematogenous routes
During our microscopic studies we detected the presence of
C33A-RFP cells in lymph vessels connecting lumbar and renal
lymph node metastases in C33A-RFP tumor-bearing mice,
thereby demonstrating the lymphatics as route of secondary
metastasis in this model (Fig. 2a, b).In addition, circulating C33A-
RFP cells were also detected in erythrocyte containing blood
vessels located next to LN-RN-connecting lymph vessels, reflecting
the hematogenous route of metastatic migration of tumor cells
(Fig. 2c). Notably, fluorescence imaging revealed RFP signals in
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lungs of C33A-RFP tumor-bearing mice which usually is the first
organ to get metastasized in case of metastatic spread via the
hematogenous route. Up to day 28 post tumor cell implantation
no lung was found to be positive for RFP, whereas at day 35 three
out of six and at day 49 five out of six lungs were tested positive for
RFP spots (Fig. 2d).
Figure 1. Formation of tumors and lymph node metastases after subcutaneous implantation of 56106 C33A-RFP cells. Tumors and
lymph nodes of six to seven mice per time point were analyzed (7 and 21 dpti: n = 7; 14, 28, 35 and 49 dpti: n = 6). a Bright field (BF), RFP and overlay
images of C33A-RFP cells, scale bar represents 100 mm. b Time curve of C33A-RFP tumor growth. c Volume of lumbar and renal lymph nodes over
time. d Representative images of tumors (upper row) and corresponding lymph nodes (lower row) of C33A-RFP tumor-bearing mice at the indicated
days post tumor cell implantation. Images of tumors (T) were taken of living mice using the Maestro EX Imaging System. Imaging of lumbar (LN1,
LN2) and renal (RN1, RN2) lymph node metastases in the abdomen of tumor-bearing mice was performed post mortem, after opening the abdomen
and removing organs. Scale bars represent 2 mm. e Percentage of all lymph nodes positive for RFP over time. f Percentage of LN1, LN2, RN1 and RN2,
respectively, positive for RFP per time point.
doi:10.1371/journal.pone.0098533.g001
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In summary, we clearly demonstrated that C33A-RFP cells are
using the lymphatic as well as the hematogenous routes for
metastatic spread in s.c. implanted tumor-bearing nude mice.
Furthermore, we observed an accumulation of the RFP signal in
kidneys of these mice by fluorescence imaging during the time
course of 49 days (Fig. 3). Histological analysis of tumors, LNs and
RNs of tumor-bearing mice 31 dpti revealed an organized
structure of RFP expressing C33A cells in tumors and lymph
node metastases, which was not true for RFP in kidneys (Fig. 4a).
Furthermore, we showed that the renal RFP signals were located
mainly in the cortex and CD31 labeled blood vessels in the
medulla and pelvis of the kidneys (Fig. 4b). Images of the renal
cortex with higher magnification revealed RFP accumulation in
nephrons, whereby RFP seemed to be located cell-independently
in spot-like patterns (Fig. 4c). No micrometastases were observed
in kidneys. Therefore, we assume that the strong RFP signal in
kidneys of C33A-RFP tumor-bearing mice might be caused by
deposition of RFP in renal cortex, after blood filtering in nephrons.
In contrast to what we observed in the kidneys, micrometastases
were detected in lungs of C33A-RFP tumor-bearing mice 42 dpti
(Fig. 4d left). Moreover, single C33A-RFP cells were found in
blood vessels of lungs as well as RFP fragments similar to those
observed in the renal cortex of the kidneys (Fig. 4d right).
Taken together, histological analyses revealed a clear, organized
structure of RFP expressing C33A cells in tumors and lymph node
metastases, whereas the RFP signal in kidneys seemed to be mainly
the result of protein deposition and not only of metastasized RFP
positive tumor cells. RFP signal in lungs seemed to be caused by
both, metastasized and settled C33A-RFP cells and RFP
deposition.
Detection of viable C33A-RFP cells in tumors, LNs, RNs,
lungs and kidneys of tumor-bearing mice
To further investigate whether the RFP signal in tumors, LNs,
RNs, lungs and kidneys of C33A-RFP tumor bearing mice
resulted from viable C33A cells, single cell suspensions of these
tissues of 5 mice 49 dpti were prepared and analyzed by FACS.
We found that 83% of the cells in tumor cell suspensions were
positive for RFP, 42% in LN, 32% in RN, 11% in lung and 18%
in kidney suspensions (Fig. 5a). Hence, RFP positive tumor cells
were detectable in all analyzed tissues of C33A-RFP tumor-
bearing mice.
To determine how many of these RFP positive cells were indeed
viable tumor cells, we performed a blasticidin selection assay. After
one week of blasticidin selection media consumption (indicated by
changing of the color of phenol red from red to yellow) correlated
with the amount of viable cells (Fig. 5b, left). Crystal violet staining
showed additionally that tumor, LN and RN suspensions
contained more viable C33A-RFP cells than lung and kidney
suspensions (Fig. 5b, right). Only a few positive C33A-RFP cell
colonies were observed in wells of lung and kidney suspensions in
1021 dilutions, whereas RFP positive cells were noticed in all
dilutions of the tumor, LN and RN suspensions.
Subsequently, the stained C33A-RFP cell colonies were counted
in the appropriate dilutions and the number of colony forming
C33A-RFP cells per gram tissue was determined for tumors,
metastases and organs. It turned out that 8.66106 (62.96106)
colony forming C33A-RFP cells were detected per gram tumor
tissue, 1.76107 (65.96106) in LN and 1.56107 (61.76107) in
RN. In contrast to this only 4.86103 (69.76103) colony forming
C33A-RFP cells were detected in lungs and 8.16103 (61.76104)
in kidneys (Fig. 5c).
Figure 2. Metastatic migration of the C33A-RFP cells in tumor-bearing nude mice. a Migration of C33A-RFP cells in a lymph vessel
connecting LN1 and RN1 42 dpti. Scale bars represent 2 mm. b LYVE-1 staining of 100 mm cross sections of the part between LN1 and RN1. Scale bars
represent 200 mm. c Migration of C33A-RFP cells in a lymph (filled arrowhead) and in an erythrocyte containing blood vessel (open arrowhead) 32
dpti. Scale bars represent 2 mm (left) and 500 mm (right). d RFP signals in lungs of C33A-RFP tumor-bearing mice. Above: representative image of a
lung 42 dpti. Scale bar represents 2 mm. Below: percentage of lungs tested positive for RFP spots over time. Lungs of six to seven mice per time point
were examined (7 and 21 dpti: n = 7; 14, 28, 35 and 49 dpti: n = 6).
doi:10.1371/journal.pone.0098533.g002
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Thus, we demonstrated a significant lower amount of viable
C33A-RFP cells in lungs and kidneys than in tumors and lymph
node metastases of tumor-bearing mice, revealing that C33A-RFP
metastases formation occurs mainly via the lymphatic route.
Combating metastases in the C33A-RFP model
Once, metastatic spread of C33A-RFP cells in nude mice after
s.c. implantation of tumor cells was characterized, we set out to
analyze the possibility of an oncolytic virotherapy as a novel
treatment option for C33A-RFP tumors and metastases. Recently,
it has been shown, that the oncolytic vaccinia virus GLV-1h68 is
an efficient agent in fighting hematogenous as well as lymphatic
metastases in the human prostate cancer model PC-3 [22,27].
Based on this, GLV-1h68 seems to be a promising candidate to
eradicate C33A-RFP metastases. Initially, 12 C33A-RFP tumor-
bearing mice were injected 11 dpti with 56106 plaque forming
units (pfu) of GLV-1h68 or PBS as a control, respectively. As early
as 14 days after virus/PBS injection (dpi) tumor volume in the
GLV-1h68 treated group started to decrease. From 18 dpi on a
statistical significant reduction of the C33A-RFP tumor volumes
was achieved due to virus treatment when compared to the PBS
treated control tumors (Fig. 6a). Tumor volumes were reduced to
the initial size. Histological analyses of virus treated and control
tumors 21 dpi revealed a massive spreading of GLV-1h68 in
tumors of the virus group, associated with a lower fluorescence
intensity of RFP and Hoechst, indicating virus-mediated, pro-
nounced necrosis of tumor tissue (Fig. 6b). Furthermore, volumes
of lumbar and renal lymph nodes in the PBS group were
significantly higher when compared to those in the virus treated
group 21 dpi, indicating a metastases inhibiting effect of GLV-
1h68 (Fig. 6c). In further analyses, lymph nodes positive for C33A-
RFP were determined by fluorescence microscopy. It turned out
that 16 out of 22 enlarged lymph nodes (72.3%) were positive for
RFP in the PBS group, whereas only 1 out of 15 enlarged lymph
nodes (6.7%) was tested positive for RFP in the GLV-1h68 treated
group (Fig. 6d), demonstrating the virus-mediated therapeutic
effect on lymph node metastasis formation. Moreover, microscop-
ical analyses of lumbar lymph node metastasis sections showed
that neither RFP nor virus encoded GFP is detectable 21 days
after virus injection. In contrast to this, a strong RFP signal was
detected in lymph nodes of PBS treated C33A-RFP tumor bearing
mice. Eventually, RFP in kidneys and lungs of C33A-RFP tumor
bearing mice was analyzed microscopically and compared in PBS
and virus treated groups. In both cases a drastic reduction of RFP
was observed due to virus treatment (Fig. 6f, g).
Altogether, we demonstrated an efficient virus-mediated reduc-
tion of tumor size and metastatic burden in C33A-RFP tumor-
bearing mice 21 dpi.
Discussion
Since metastatic spread of carcinomas represents the major
cause of cancer related death, there is an urgent need to intensify
research focusing on the field of tumor metastasis. A lot of effort
has been put into establishing metastatic models. Here, we
describe the yet unpublished metastasizing ability of the HPV
negative human cervical cancer cell line C33A in athymic nude
mice after subcutaneous implantation of tumor cells, offering a
new platform to analyze cancer metastasis and to test novel
treatment modalities.
First of all, we observed an enlargement of lumbar and renal
lymph nodes in C33A tumor-bearing mice (data not shown).
Volume expansion of lymph nodes might be caused by an
increasing amount of immigrating C33A cells, by an invasion of
immune cells and/or might be a consequence of the premetastatic
state of lymph nodes, which is due to hyperplasia and excessive
proliferation of the lymph sinus endothelium. By inserting the
cDNA encoding for mRFP1 into the C33A cell genome, we
generated a simple optical method to visualize metastatic spread of
RFP positive tumor cells. In this study, we followed the fate of
C33A-RFP cells after generation of subcutaneous tumors in
athymic mice. In case of C33A-RFP tumor-bearing mice, RFP
expressing tumor cells were detected in lumbar and renal lymph
nodes, demonstrating that the enlargement of lymph nodes was
mainly caused by metastasizing tumor cells. The constantly
increasing amount of RFP positive lymph nodes over time showed
a steady progression of lymph node metastases in correlation with
tumor growth. Since we detected metastasized C33A-RFP cells 7
dpti only in LN1, this lymph node seemed to be the first target of
metastasizing tumor cells, indicating metastasis of regional
draining lymph nodes, a frequently described phenomenon for
lymphatic metastasis [28–30]. The spread of cervical carcinomas
to regional lymph nodes is a common hallmark of metastases and
one of the primary determinants of outcome for patients [3,4].
Moreover, at later stages we detected C33A-RFP cells in lymph
vessels connecting regional lumbar and distant renal lymph node
Figure 3. RFP signals in kidneys of C33A-RFP tumor-bearing mice 7, 14, 21, 28 and 35 dpti. Six to seven mice were analyzed per time
point (7 and 21 dpti: n = 7; 14, 28 and 35 dpti: n = 6). a Representative images of RFP signal in kidneys. Upper row: overlay of bright field and RFP
images. Lower row: images of RFP signal. Scale bars represent 2 mm. b Mean fluorescence intensity of the RFP signal in kidneys of C33A-RFP tumor-
bearing mice over time.
doi:10.1371/journal.pone.0098533.g003
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metastases. Thereby, we demonstrated that metastatic tumor cells
can enter the lymphatic circulation and produce additional
metastases, a process known as metastasis of metastases [31]. This
pattern of metastatic tumor cell spread within the lymph system is
a well described feature of many carcinomas [32–33].
Besides lymphatic metastases, we demonstrated the hematoge-
nous spread of tumor cells in C33A-RFP tumor-bearing mice.
Migrating C33A-RFP cells were on the one hand directly detected
in blood vessels and on the other hand RFP positive microme-
tastases were observed in lungs of tumor-bearing mice. We further
observed a very strong RFP signal in kidneys of C33A-RFP tumor-
bearing mice. Histological analyses revealed an organized cellular
localization of RFP in C33A cells in tumors, LNs and RNs,
whereas RFP in kidneys was mainly located in the cortex area in
spot-like patterns. A massive growth of primary tumors often leads
to the development of hypoxic tumor regions. Hypoxia can
Figure 4. Histological analysis of tumors, LNs, RNs and kidneys of C33A-RFP tumor-bearing mice. Nuclei in a, b and c were stained with
Hoechst dye. a Overlays of bright field, RFP and Hoechst images of 10 mm sections of a tumor, LN, RN and kidney 31 dpti. Scale bars represent 50 mm.
b Images of 100 mm sections of a kidney 31 dpti, stained with anti-CD31 antibody and Hoechst dye. Scale bar represents 2 mm. c 10 mm kidney
section stained with Hoechst dye. Right: confocal image. Scale bars represent 100 mm (left) and 10 mm (right). d CD31 and Hoechst staining of
100 mm lung sections 42 dpti. Filled arrowhead: in a blood vessel migrating C33A-RFP cell; empty arrowhead: RFP positive fragments. Scale bars
represent 250 mm (left) and 50 mm (right). All images are representative examples.
doi:10.1371/journal.pone.0098533.g004
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influence tumor cells by acting as a stressor that impairs growth or
causes cell death [34]. Dying C33A-RFP cells release red
fluorescent proteins into the blood stream. As blood is filtered in
the kidney nephrons, RFP can possibly be deposited in those
structures. Furthermore, by FACS analyses and a blasticidin-
survival study we assessed that the amount of viable C33A-RFP
cells in kidneys was relatively small in comparison to the observed
strong RFP signal. Therefore, we assume that the RFP signal in
kidneys is caused in a higher degree by deposition of RFP than by
the low number of RFP expressing metastasized tumor cells.
Moreover, RFP might be associated with cell fragments, or taken
up in vesicles.
In contrast to lungs and kidneys with only 5000 and 8000 viable
tumor cells per gram tissue, respectively, about 15 million viable
C33A-RFP cells per gram were present in lumbar and renal lymph
nodes, suggesting lymph nodes as the main targets of metastasizing
tumor cells in the C33A model. Lymphatic metastasis is known to
be the main metastatic route of many cervical carcinomas in
patients [17,35].
Besides characterizing the metastatic behavior of C33A-RFP
cells in nude mice, we analyzed the potential of oncolytic
virotherapy for the treatment of primary tumors and their
metastases in this model. While oncolytic virotherapy was already
tested as a treatment option in C33A tumor-bearing mice, the
therapeutic effect on metastases was not investigated. For example,
Unno et al. treated cervical cancer with Sindbis virus [36] and Kim
et al. analyzed the effect of an oncolytic adenovirus on cervix
carcinomas [37]. Here, we set out for the first time to study the
influence of the previously described oncolytic vaccinia virus
GLV-1h68 [20–21] on C33A-RFP tumors as well as metastases.
We observed a drastic reduction of the primary C33A-RFP tumor
size due to virus treatment, indicating that this model is –
responding well to vaccinia virus-mediated oncolytic virotherapy.
Comparable treatment responses have been demonstrated in a
variety of other tumor models, for example, in human malignant
pleural mesothelioma [38], human pancreatic tumor xenografts
[23] or anaplastic thyroid cancer [39]. A first indicator for an anti-
metastatic effect of GLV-1h68 was evident by a significant
decrease of the lymph node volume following virus treatment.
Furthermore, a radical reduction of lymph nodes positive for
metastasized C33A-RFP cells was observed in the virus-treated
mice 21 dpi. Histological anaylsis revealed that neither RFP nor
virus-encoded GFP signals were detectable in the majority of
lymph nodes after virus treatment. We assume, on the one hand,
that the massive viral colonization of the primary tumor caused a
reduction of C33A-RFP cell migration to lymph nodes, and on the
other hand that GLV-1h68 infection resulted in destruction of the
already migrated and settled C33A-RFP cells in lymph nodes.
Figure 5. Analysis of tumor, LN, RN, lung and kidney single cell suspensions from C33A-RFP tumor-bearing mice 49 dpti. Tissues of
all 5 mice were analyzed (n = 5). a Amount of RFP positive (RFP+) and negative (RFP-) cells in single cell suspensions of tumor, LN, RN, lung and
kidneys. 10,000 events were analyzed by FACS. b Growth of different dilutions (1021–1024) of C33A-RFP single cell suspensions in wells of 24-well
plates after one week of blasticidin selection. Left image: media consumption in wells containing 2 days old media. Right image: wells after staining
with crystal violet. c Numbers of colony forming C33A-RFP cells per gram tumor, LN, RN, lung and kidney, respectively. Cell colonies were counted for
each organ after blasticidin-selection and crystal violet staining.
doi:10.1371/journal.pone.0098533.g005
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Hence, there was an efficient diminishment of RFP expressing
tumor cells in lumbar and renal lymph nodes by virus treatment.
Without C33A-RFP tumor cells in the lymph nodes GLV-1h68
has no target structures to replicate in, explaining the absence of a
GFP signal. In addition, a drastic virus-mediated reduction of RFP
in lungs and kidneys of C33A-RFP tumor-bearing mice was
Figure 6. Influence of oncolytic virotherapy on C33A-RFP tumors and metastases. a Time curve of C33A-RFP tumor growth in 12 mice
after administration of the oncolytic vaccinia virus GLV-1h68 and PBS, respectively (n = 6). Analyses of C33A-RFP tumors and metastases in b-g were
done 32 dpti and 21 days after administration of GLV-1h68 or PBS (dpi). Six mice were examined per group (n = 6). b Left: C33A-RFP tumor-bearing
mice 21 dpi. Right: 100 mm sections of a PBS and a GLV-1h68 treated tumor. Nuclei were stained with Hoechst dye, GFP is expressed by GLV-1h68 and
RFP by C33A cells. c Volume of lumbar and renal lymph nodes and d percentage of RFP positive lymph nodes in PBS and GLV-1h68 treated C33A-RFP
tumor-bearing mice (left). Right: Images of lumbar and renal lymph nodes in PBS and GLV-1h68 treated mice. e 100 mm sections of a PBS (left) and a
GLV-1h68 (right) treated lumbar lymph node metastasis. f Left: Percentage of kidneys positive for RFP in PBS and GLV-1h68 treated mice. Right:
Images of kidneys in the PBS and virus group. g Percentage of lungs positive for RFP in PBS and GLV-1h68 group. All images are representative
examples. All scale bars represent 2 mm.
doi:10.1371/journal.pone.0098533.g006
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demonstrated. As discussed above, the RFP reduction in kidneys
might not be necessarily caused only by elimination of metastatic
cells. In fact, we assume that there is a decrease in RFP deposition
in kidneys after blood filtering, since the majority of RFP
expressing tumor cells in mice seemed to be diminished earlier
than three weeks after virus injection, due to viral infection and
elimination of RFP positive cells. All in all, we showed that the
oncolytic vaccinia virus GLV-1h68 has a great therapeutic
potential in treating tumors as well as metastases of the cervical
cancer cell line C33A.
Conclusions
Since metastatic carcinomas represent a major health problem,
it is crucial to intensify metastasis research. Here, we characterize
the yet unknown metastatic behavior of the human cervical cancer
cell line C33A in nude mice. We showed that C33A-RFP cells
migrate from primary tumors at the flank of nude mice to lumbar
and renal lymph node pairs, resulting in formation of lymph node
metastases. The progression of lymph node metastases correlated
with tumor growth, as seen in the clinic. Besides predominantly
occurring lymphatic metastases, hematogenous spreading of
C33A-RFP cells was detected. Furthermore, we analyzed the
influence of oncolytic virotherapy on C33A-RFP tumors and
metastases and demonstrated an efficient virus-mediated reduction
of tumor size as well as metastatic burden.
Taken together, we hypothesize, that the C33A(-RFP) model
might serve as a new platform to analyze cancer metastases and to
test novel treatment modalities to efficiently fight metastases.
Supporting Information
Table S1 HPV-status of different cervical cancer cell lines and
their response to oncolytic vaccinia virus therapy. Different
cervical cancer cell lines were screened for the effects of oncolytic
virus therapy with GLV-1h68. The plus (+) in the second column
indicates the presence of HPV DNA in cancer cells, minus (-) the
absence. Plus in the last column means a successful regression of
the tumor after virus administration, while minus in this column
indicates that virus administration had no effects on tumor growth.
(DOCX)
Acknowledgments
The authors thank S. Wittber for excellent animal care, T. Trevino for
technical assistance, Drs. Q. Zang and Y.A. Yu for providing the rVACV
GLV-1h68 and Dr. C. Seubert for providing data regarding oncolytic
therapy of SiHa and CaSki.
Author Contributions
Conceived and designed the experiments: UD SS AAS. Performed the
experiments: UD JR SS BH CK JLL. Analyzed the data: UD JR.
Contributed reagents/materials/analysis tools: NGC RJA. Wrote the
paper: UD SW JS MH AAS.
References
1. Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer
metastasis: historical perspective. Cancer Res 70: 5649–5669.
2. Sugarbaker PH (1981) Carcinoma of the colon—prognosis and operative choice.
Curr Probl Surg 18: 753–802.
3. Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, et al. (2007)
Patterns of metastasis in human solid cancers. Cancer Treat Res 135: 209–221.
4. Khanna C, Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26:
513–523.
5. Pearson HB, Pouliot N (2012) Modeling Metastasis In Vivo.
6. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR (2003) In vivo
monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6
cells in murine models of human prostate cancer. Clin Exp Metastasis 20: 745–
756.
7. Triest JA, Grignon DJ, Cher ML, Kocheril SV, Montecillo EJ, et al. (1998)
Systemic interleukin 2 therapy for human prostate tumors in a nude mouse
model. Clin Cancer Res 4: 2009–2014.
8. Bastide C, Bagnis C, Mannoni P, Hassoun J, Bladou F (2002) A Nod Scid mouse
model to study human prostate cancer. Prostate Cancer Prostatic Dis 5: 311–
315.
9. Gu J, Zhao J, Li Z, Yang Z, Zhang J, et al. (2003) Clinical application of
radioimmunoguided surgery in colorectal cancer using 125I-labeled carcinoem-
bryonic antigen-specific monoclonal antibody submucosally. Dis Colon Rectum
46: 1659–1666.
10. Tsutsumi S, Kuwano H, Morinaga N, Shimura T, Asao T (2001) Animal model
of para-aortic lymph node metastasis. Cancer Lett 169: 77–85.
11. Chen J, Stavro PM, Thompson LU (2002) Dietary flaxseed inhibits human
breast cancer growth and metastasis and downregulates expression of insulin-like
growth factor and epidermal growth factor receptor. Nutr Cancer 43: 187–192.
12. Li X, Wang J, An Z, Yang M, Baranov E, et al. (2002) Optically imageable
metastatic model of human breast cancer. Clin Exp Metastasis 19: 347–350.
13. Yamaguchi K, Ura H, Yasoshima T, Shishido T, Denno R, et al. (2000)
Establishment and characterization of a human gastric carcinoma cell line that is
highly metastatic to lymph nodes. J Exp Clin Cancer Res 19: 113–120.
14. Fujihara T, Sawada T, Hirakawa K, Chung YS, Yashiro M, et al. (1998)
Establishment of lymph node metastatic model for human gastric cancer in nude
mice and analysis of factors associated with metastasis. Clin Exp Metastasis 16:
389–398.
15. An Z, Jiang P, Wang X, Moossa AR, Hoffman RM (1999) Development of a
high metastatic orthotopic model of human renal cell carcinoma in nude mice:
benefits of fragment implantation compared to cell-suspension injection. Clin
Exp Metastasis 17: 265–270.
16. Cairns RA, Hill RP (2004) A fluorescent orthotopic model of metastatic cervical
carcinoma. Clin Exp Metastasis 21: 275–281.
17. Duan P, Duan G, Liu YJ, Zheng BB, Hua Y, et al. (2012) Establishment of a
visualized nude mouse model of cervical carcinoma with high potential of lymph
node metastasis via total orthotopic transplantation. Eur J Gynaecol Oncol 33:
472–476.
18. Cairns RA, Hill RP (2004) Acute hypoxia enhances spontaneous lymph node
metastasis in an orthotopic murine model of human cervical carcinoma. Cancer
Res 64: 2054–2061.
19. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE (2007) Oncolytic viruses in
cancer therapy. Cancer Lett 254: 178–216.
20. Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, et al. (2009) The highly
attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative
genomic features and the contribution of F14.5L inactivation. Mol Genet
Genomics 282: 417–435.
21. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, et al. (2007) Eradication of
solid human breast tumors in nude mice with an intravenously injected light-
emitting oncolytic vaccinia virus. Cancer Res 67: 10038–10046.
22. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, et al. (2010)
Regression of human prostate tumors and metastases in nude mice following
treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed
Biotechnol 2010: 489759.
23. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, et al. (2009) Regression of
human pancreatic tumor xenografts in mice after a single systemic injection of
recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 8: 141–151.
24. Stubenrauch F, Straub E, Fertey J, Iftner T (2007) The E8 repression domain
can replace the E2 transactivation domain for growth inhibition of HeLa cells by
papillomavirus E2 proteins. Int J Cancer 121: 2284–2292.
25. Weibel S, Raab V, Yu YA, Worschech A, Wang E, et al. (2011) Viral-mediated
oncolysis is the most critical factor in the late-phase of the tumor regression
process upon vaccinia virus infection. BMC Cancer 11: 68.
26. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA (2008) Colonization of
experimental murine breast tumours by Escherichia coli K-12 significantly alters
the tumour microenvironment. Cell Microbiol 10: 1235–1248.
27. Donat U, Weibel S, Hess M, Stritzker J, Hartl B, et al. (2012) Preferential
Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a
Human PC-3 Prostate Cancer Model in Nude Mice. PLoS One 7: e45942.
28. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung
cancer staging. Chest 111: 1718–1723.
29. Smith JA, Jr., Whitmore WF, Jr. (1981) Regional lymph node metastasis from
bladder cancer. J Urol 126: 591–593.
30. Crede RH, Benjamin JE, et al. (1949) Primary carcinoma of the liver
(cholangioma) with regional lymph node and bilateral ovarian metastases.
Cinci J Med 30: 139–144.
31. Langley RR, Fidler IJ (2007) Tumor cell-organ microenvironment interactions
in the pathogenesis of cancer metastasis. Endocr Rev 28: 297–321.
32. Karkkainen MJ, Makinen T, Alitalo K (2002) Lymphatic endothelium: a new
frontier of metastasis research. Nat Cell Biol 4: E2–5.
Metastasis and Virotherapy of a C33A Cancer Model
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e98533
33. Sleeman JP (2000) The lymph node as a bridgehead in the metastatic
dissemination of tumors. Recent Results Cancer Res 157: 55–81.
34. Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory
mechanisms, and cellular response. Oncologist 9 Suppl 5: 4–9.
35. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, Ihling C, Hogerle S, et al. (2001)
Metastatic lymph nodes in patients with cervical cancer: detection with MR
imaging and FDG PET. Radiology 218: 776–782.
36. Unno Y, Shino Y, Kondo F, Igarashi N, Wang G, et al. (2005) Oncolytic viral
therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin
Cancer Res 11: 4553–4560.
37. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, et al. (2006) Relaxin expression
from tumor-targeting adenoviruses and its intratumoral spread, apoptosis
induction, and efficacy. J Natl Cancer Inst 98: 1482–1493.
38. Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, et al. (2008) Novel oncolytic agent
GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther
19: 774–782.
39. Lin SF, Price DL, Chen CH, Brader P, Li S, et al. (2008) Oncolytic vaccinia
virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 93:
4403–4407.
Metastasis and Virotherapy of a C33A Cancer Model
PLOS ONE | www.plosone.org 11 June 2014 | Volume 9 | Issue 6 | e98533
